Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Concurrent Lymphoid Malignancy

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2011 Sep 13

PMID 21909142

Citations 4

Authors

Z Zimmerman

B L Scott

A K Gopal

B M Sandmaier

D G Maloney

H J Deeg

Affiliations

Soon will be listed here.

Abstract

Allogeneic hematopoietic cell transplantation (HCT) can be curative for both myelodysplastic syndromes (MDS) and lymphoid malignancies. Little is known about the efficacy of allogeneic HCT in patients in whom both myeloid and lymphoid disorders are present at the time of HCT. We analyzed the outcomes in 21 patients with MDS and concurrent lymphoid malignancy when undergoing allogeneic HCT. A total of 17 patients had previously received extensive cytotoxic chemotherapy, including autologous HCT in 7, for non-Hodgkin lymphoma (NHL, n=7), Hodgkin lymphoma (HL, n=2), CLL (n=5), NHL plus HL (n=1), multiple myeloma (n=1) or T-cell ALL (n=1), and had presumably developed MDS as a consequence of therapy. Four previously untreated patients had CLL. A total of 19 patients were conditioned with high-dose (n=14) or reduced-intensity regimens (n=5), and were transplanted from HLA-matched or one Ag/allele mismatched related (n=10) or unrelated (n=9) donors; two patients received HLA-haploidentical related transplants, following a modified conditioning regimen. Currently, 2 of 4 previously untreated and 2 of 17 previously treated patients are surviving in remission of both MDS and lymphoid malignancies. However, the high non-relapse mortality among previously treated patients, even with reduced-intensity conditioning regimens, indicates that new transplant strategies need to be developed.

Citing Articles

The Contemporary Role of Hematopoietic Stem Cell Transplantation in the Management of Chronic Myeloid Leukemia: Is It the Same in All Settings?.

Elmakaty I, Saglio G, Al-Khabori M, Elsayed A, Elsayed B, Elmarasi M Cancers (Basel). 2024; 16(4).

PMID: 38398145 PMC: 10886670. DOI: 10.3390/cancers16040754.

Reply to 'allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome'.

Schroeder T, Fenk R, Haas R, Germing U, Kobbe G Bone Marrow Transplant. 2015; 50(11):1483-5.

PMID: 26237167 DOI: 10.1038/bmt.2015.176.

Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome.

Nishihori T, Komrokji R, Shain K, Anasetti C Bone Marrow Transplant. 2014; 50(2):296-7.

PMID: 25330222 DOI: 10.1038/bmt.2014.233.

Reduced-intensity allogeneic stem cell transplantation for co-emergence of chemotherapy-refractory follicular lymphoma and therapy-related myelodysplastic syndrome.

Shimura Y, Kuroda J, Sasaki N, Uchiyama H, Ohshiro M, Matsumura Y Case Rep Oncol. 2014; 7(1):188-94.

PMID: 24748869 PMC: 3985782. DOI: 10.1159/000360905.

References

Sylvester L, Nowell P, Bonner H, Moreau L, Moore J . Concurrent diagnosis of chronic lymphocytic leukemia and myelodysplastic syndrome. Leuk Res. 1997; 21(7):619-21. DOI: 10.1016/s0145-2126(97)00017-9. View

Mossafa H, Fourcade C, Pulic M, Jary L, Cheze S, Troussard X . Chronic lymphocytic leukemia associated with myelodysplastic syndrome and/or chronic myeloid leukemia: evidence for independent clonal chromosomal evolution. Leuk Lymphoma. 2001; 41(3-4):337-41. DOI: 10.3109/10428190109057988. View

Andre M, Mounier N, Leleu X, Sonet A, Brice P, Henry-Amar M . Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood. 2003; 103(4):1222-8. DOI: 10.1182/blood-2003-04-1124. View

Parmar S, de Lima M . Hematopoietic stem cell transplantation for myelodysplastic syndrome. Biol Blood Marrow Transplant. 2009; 16(1 Suppl):S37-44. DOI: 10.1016/j.bbmt.2009.10.018. View

Przepiorka D, Weisdorf D, MARTIN P, Klingemann H, Beatty P, Hows J . 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15(6):825-8. View

Aviv H, Tang D, Das K, Harrison J, Hameed M, Varma M . Simultaneous appearance of trisomy 8 and trisomy 12 in different cell populations in a patient with untreated B-cell chronic lymphocytic leukemia and myelodysplasia. Leuk Lymphoma. 2004; 45(6):1279-83. DOI: 10.1080/10428190310001638869. View

Rosenbloom B, Schreck R, Koeffler H . Therapy-related myelodysplastic syndromes. Hematol Oncol Clin North Am. 1992; 6(3):707-22. View

Lee S, Vogelsang G, Flowers M . Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003; 9(4):215-33. DOI: 10.1053/bbmt.2003.50026. View

Wrench D, Gribben J . Stem cell transplantation for non-Hodgkin's lymphoma. Hematol Oncol Clin North Am. 2008; 22(5):1051-79, xi. DOI: 10.1016/j.hoc.2008.07.007. View

10.

Mitterbauer G, Schwarzmeier J, Mitterbauer M, Jaeger U, Fritsch G, Schwarzinger I . Myelodysplastic syndrome/acute myeloid leukemia supervening previously untreated chronic B-lymphocytic leukemia: demonstration of the concomitant presence of two different malignant clones by immunologic and molecular analysis. Ann Hematol. 1997; 74(4):193-7. DOI: 10.1007/s002770050282. View

11.

Greenberg P, Cox C, LeBeau M, Fenaux P, Morel P, Sanz G . International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-88. View

12.

Storb R, Deeg H, Whitehead J, Appelbaum F, Beatty P, Bensinger W . Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986; 314(12):729-35. DOI: 10.1056/NEJM198603203141201. View

13.

Rawstron A, Bennett F, OConnor S, Kwok M, Fenton J, Plummer M . Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008; 359(6):575-83. DOI: 10.1056/NEJMoa075290. View

14.

Landgren O, Albitar M, Ma W, Abbasi F, Hayes R, Ghia P . B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med. 2009; 360(7):659-67. PMC: 7015348. DOI: 10.1056/NEJMoa0806122. View

15.

Leone G, Pagano L, Ben-Yehuda D, Voso M . Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007; 92(10):1389-98. DOI: 10.3324/haematol.11034. View

16.

Fozza C, Contini S, Galleu A, Simula M, Virdis P, Bonfigli S . Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset. Exp Hematol. 2009; 37(8):947-55. DOI: 10.1016/j.exphem.2009.04.009. View

17.

de Lima M, Giralt S, Thall P, de Padua Silva L, Jones R, Komanduri K . Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010; 116(23):5420-31. PMC: 5669059. DOI: 10.1002/cncr.25500. View

18.

Sato N, Nakazato T, Kizaki M, Ikeda Y, Okamoto S . Transformation of myelodysplastic syndrome to acute lymphoblastic leukemia: a case report and review of the literature. Int J Hematol. 2004; 79(2):147-51. DOI: 10.1532/ijh97.03137. View

19.

Petersdorf E, Longton G, Anasetti C, Mickelson E, McKinney S, Smith A . Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood. 1997; 89(5):1818-23. View

20.

Chang C, Storer B, Scott B, Bryant E, Shulman H, Flowers M . Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent.... Blood. 2007; 110(4):1379-87. PMC: 1939908. DOI: 10.1182/blood-2007-02-076307. View